logo

Applied Therapeutics Inc. (APLT)



Trade APLT now with
  Date
  Headline
1/23/2020 9:36:24 PM Applied Therapeutics Announces Pricing Of Its Public Offering Of 2.74 Mln Shares At $45.50/shr
1/8/2020 7:16:09 AM Applied Therapeutics Announces Positive Topline Results From Pivotal Phase 2 ACTION-Galactosemia Study Of AT-007
9/17/2019 7:01:41 AM Applied Therapeutics To Present Preclinical Data Highlighting AT-001
9/13/2019 7:08:27 AM Applied Therapeutics To Present Data Highlighting AT-001 For Diabetic Cardiomyopathy At HFSA Annual Scientific Meeting
9/4/2019 7:06:22 AM Applied Therapeutics Begins Phase 3 Registrational Trial Of AT-001 In Diabetic Cardiomyopathy (ARISE-HF)
8/12/2019 7:14:59 AM Applied Therapeutics Q2 Loss Per Share $0.60 Vs Loss $0.58 Last Year
6/24/2019 7:11:04 AM Applied Therapeutics Begins Phase 1/2 Study Of AT-007 In Galactosemia
6/21/2019 7:09:45 AM Applied Therapeutics Q1 Net Loss $8.7 Mln Or $1.58 Per Share
6/7/2019 7:35:40 AM Applied Therapeutics To Present Data Highlighting AT-001 For Diabetic Cardiomyopathy At ADA
5/28/2019 7:37:46 AM Applied Therapeutics Reports FDA Orphan Drug Designation For AT-007
  
 
>